Literature DB >> 18284273

Understanding and addressing adherence issues in schizophrenia: from theory to practice.

Peter J Weiden1.   

Abstract

If an easy answer to the problem of medication nonadherence in schizophrenia existed, it would have already been found. Despite the magnitude of the problem, in the past decade, significant advances have been made in understanding the nature of the adherence problem in schizophrenia. Just as there is no single adherence intervention but a range of interventions that can be matched to the specific challenges of the individual patient, there is not a single theory that explains adherence and non-adherence. Rather, there are a range of theories and concepts, with their own strengths and limitations. The goal of this article is to help provide a crosswalk from some of the emerging theories and concepts to practical clinical management approaches. To enhance understanding of this complex issue and help practitioners implement practical therapeutic interventions that encourage adherence, the following 5 theories regarding medication adherence are presented and suggestions made for applying them in clinical practice: (1) Adherence is not a clinical outcome and only matters as it interferes with outcome. (2) In schizophrenia, adherence problems are often entangled with efficacy limitations of antipsychotics. (3) Adherence can be viewed as a behavior (taking/not taking) or an attitude (prefers taking/prefers stopping). (4) When considering adherence attitudes, patient belief is always reality. (5) Adherence behavior changes and fluctuates over time and should be considered as part of the illness in the context of the long-term trajectory of desired clinical outcomes such as recovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18284273

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Effectiveness of sulpiride in adult patients with schizophrenia.

Authors:  Edward Chia-Cheng Lai; Chia-Hsien Chang; Yea-Huei Kao Yang; Swu-Jane Lin; Chia-Yin Lin
Journal:  Schizophr Bull       Date:  2012-02-07       Impact factor: 9.306

3.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

Review 4.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

5.  The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Authors:  Ulla A Botha; Liezl Koen; John A Joska; John S Parker; Neil Horn; Linda M Hering; Piet P Oosthuizen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-06-18       Impact factor: 4.328

6.  Ethical considerations when treating patients with schizophrenia.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2008-04

Review 7.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

8.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

9.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

10.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; David Salkever; Eric P Slade; Xiaomei Peng; Robert R Conley
Journal:  BMC Psychiatry       Date:  2010-01-07       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.